ATE306272T1 - Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion - Google Patents

Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion

Info

Publication number
ATE306272T1
ATE306272T1 AT01964471T AT01964471T ATE306272T1 AT E306272 T1 ATE306272 T1 AT E306272T1 AT 01964471 T AT01964471 T AT 01964471T AT 01964471 T AT01964471 T AT 01964471T AT E306272 T1 ATE306272 T1 AT E306272T1
Authority
AT
Austria
Prior art keywords
receptor antagonist
aldosterone receptor
cognitive function
improve cognitive
aldosterone
Prior art date
Application number
AT01964471T
Other languages
English (en)
Inventor
Kenton N Fedde
Alfonzo T Perez
Joseph F Tooley
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE306272T1 publication Critical patent/ATE306272T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01964471T 2000-08-28 2001-08-28 Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion ATE306272T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22873800P 2000-08-28 2000-08-28
PCT/US2001/026760 WO2002017895A2 (en) 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function

Publications (1)

Publication Number Publication Date
ATE306272T1 true ATE306272T1 (de) 2005-10-15

Family

ID=22858397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01964471T ATE306272T1 (de) 2000-08-28 2001-08-28 Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion

Country Status (10)

Country Link
US (2) US20020111337A1 (de)
EP (1) EP1313485B1 (de)
JP (1) JP2004507495A (de)
AT (1) ATE306272T1 (de)
AU (1) AU2001285318A1 (de)
CA (1) CA2419256A1 (de)
DE (1) DE60114027T2 (de)
DK (1) DK1313485T3 (de)
ES (1) ES2251505T3 (de)
WO (1) WO2002017895A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513024A (ja) 2001-11-23 2005-05-12 アクゾ・ノベル・エヌ・ベー グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療
PL372055A1 (en) * 2002-04-26 2005-07-11 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
AU2003278434A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
JPWO2004060400A1 (ja) * 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20090265215A1 (en) * 2008-04-22 2009-10-22 Paul Bernhard Lindstrom Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
EP2665707B1 (de) 2011-01-20 2017-01-18 Merck Sharp & Dohme Corp. Mineralkortikoid-rezeptorantagonisten
EP2697203B1 (de) 2011-04-13 2017-05-24 Merck Sharp & Dohme Corporation Mineralkortikoid-rezeptorantagonisten
EP2765860B1 (de) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Mineralkortikoid-rezeptorantagonisten
WO2013055608A1 (en) 2011-10-13 2013-04-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US9505730B2 (en) 2011-10-13 2016-11-29 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
US10039772B2 (en) * 2015-11-13 2018-08-07 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133012A (en) * 1961-06-28 1964-05-12 Universal Oil Prod Co Combination catalytic reforming process
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
ATE225367T1 (de) * 1996-12-11 2002-10-15 Searle & Co Verfahren zur herstellung von 3-keto-7alpha- alkoxycarbonyl- delta4,5-steroiden sowie zwischenprodukte
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
ID29778A (id) * 1998-11-06 2001-10-11 Searle & Co Pengobatan kombinasi dari penghambat enzim pengubah angiotensi dan antagonis aldosteron untuk menurunkan morbiditas dan mortalitas dari penyakit kardiovaskuler
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CA2364169A1 (en) * 1999-03-05 2000-09-08 G.D. Searle Llc Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
ES2251505T3 (es) 2006-05-01
US20020111337A1 (en) 2002-08-15
DE60114027T2 (de) 2006-07-13
US20060058274A1 (en) 2006-03-16
CA2419256A1 (en) 2002-03-07
EP1313485A2 (de) 2003-05-28
DE60114027D1 (de) 2006-02-23
AU2001285318A1 (en) 2002-03-13
WO2002017895A3 (en) 2003-02-06
JP2004507495A (ja) 2004-03-11
EP1313485B1 (de) 2005-10-12
WO2002017895A2 (en) 2002-03-07
DK1313485T3 (da) 2005-12-27

Similar Documents

Publication Publication Date Title
ATE306272T1 (de) Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
AUPO755097A0 (en) Receptor agonist and antagonist
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
LV12639B (lv) Bifenilsulfonamidi ka duali angiotenzina un endotelina receptoru antagonisti
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
ATE322290T1 (de) Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE438405T1 (de) Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
BR0313534A (pt) Antagonistas de integrinade ácido carboxìlico de piperidinoìla
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen
DZ3361A1 (fr) Cyclohéxylamines bicycliques et leur utilisation comme antagonistes des récepteurs de nmda
ATE381938T1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
MXPA06000664A (es) Antagonistas del receptor muscarinico de acetilcolina.
MXPA06000663A (es) Antagonistas del receptor muscarinico de acetilcolina.
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
DE60221275D1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
ATE310537T1 (de) Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
DE60126134D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1313485

Country of ref document: EP

REN Ceased due to non-payment of the annual fee